Showing results (251-260 of 379) with videos related to
Sort By:
Pageof 38
Frontiers in Oncology|May 3, 2021
Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant MelanomaTeresa Schmidt, Sied Kebir, Elisabeth Livingstone, et al.Journal of Translational Medicine|May 12, 2025
Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patientsKatarzyna Borys, Georg Lodde, Elisabeth Livingstone, et al.International Journal of Cancer|May 13, 2016
Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survivalMiriam Potrony, Esther Carreras, Fernando Aranda, et al.Plos One|March 12, 2015
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanomaLisa Zimmer, Julia Vaubel, Peter Mohr, et al.Nature Medicine|October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialRichard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre studyAlexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell ClonesIsabel C Poschke, Jessica C Hassel, Aaron Rodriguez-Ehrenfried, et al.European Journal of Cancer (Oxford, England : 1990)|March 8, 2025
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyPhilipp Jansen, Wolfgang Galetzka, Carl M Thielmann, et al.European Journal of Cancer (Oxford, England : 1990)|April 5, 2023
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanomaJulia Lai-Kwon, Sarah Jacques, Matteo Carlino, et al.Clinical and Translational Medicine|November 2, 2022
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotypeLea Jessica Albrecht, Anna Höwner, Klaus Griewank, et al.Pageof 38